secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0000950170-25-030824
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon reports Q4 2024 net loss $48.6M; cash $312M; key pipeline milestones for GBS and dry AMD
--------------------------------------------------------------------------------

- Cash $312.0M as of Dec 31, 2024; runway into 2H 2026.
- Net loss $48.6M Q4 2024 vs $27.9M Q4 2023; R&D expense $43.4M.
- Pre-BLA meeting for GBS drug ANX005 targeted 1H 2025; BLA submission planned.
- Global registration path for ANX007 in dry AMD with GA; Phase 3 ARCHER II data expected 2H 2026.
- ANX1502 oral C1s inhibitor POC trial ongoing; dataset in up to 7 CAD patients expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017025030824/0000950170-25-030824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017025030824/annx-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-030824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer